Navigation Links
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Date:2/19/2009

Transaction Value in Excess of $10 Million; Access Gains Second

Source Manufacturing and Significant Clinical Trial Support

DALLAS, and SEOUL, South Korea, Feb. 19 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and JCOM Ltd, an affiliate of DONG-A Pharmaceuticals, the premier pharmaceutical company in the Republic of Korea, today announced the signing of a definitive licensing agreement under which JCOM and DONG-A will manufacture, develop and commercialize Access' proprietary products ProLindac and MuGard for the Republic of Korea. ProLindac is Access' novel DACH platinum prodrug currently in Phase 2 clinical studies which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. MuGard is used for the management of oral mucositis, a debilitating side effect of many anticancer chemotherapy and radiation treatments, and has already received marketing allowance from US and European regulatory authorities.

Under the terms of the agreement JCOM will pay Access an upfront fee and subsequent milestone payments along with a double digit royalty upon commercialization of ProLindac and MuGard. In addition, in co-operation with Access, JCOM has committed to fund and execute a Phase 2 combination study for ProLindac in an indication to be determined by the Parties. This controlled Phase 2 combination study would cost up to $10 million if conducted in the US or Europe. Dong-A will be responsible for obtaining the necessary regulatory approvals for ProLindac and MuGard and commercializing the products in the Republic of Korea.

"We are very pleased to have JCOM and Dong-A as partners for ProLindac and MuGard," said Jeffrey B. Davis, Access' President & CEO. "We are excited about their commitment to rapidly start a Phase 2 study with ProLindac. This is the third major Phase 2 study to b
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...SVEGAS,Nov.23/PRNewswire-FirstCall/--CordBloodAmer...oodstemcellpreservationcompany( http://www.cordblo...ntialofstemcells,abiologicalinsurancepolicy,tofami...tanupdatedprogressinterviewwithCEOandco-founderMat...iewisat: http://blip.tv/file/2875811 . ,, Inthe...
(Date:11/23/2009)...VATO,Calif.,Nov.23/PRNewswire-FirstCall/--RaptorPh...RPTP ),todayannouncedresultsfromaPhase2bclinicaltr...rate("DRCysteamine")inpatientswithnephropathiccyst...sityofCalifornia,SanDiego("UCSD")GeneralClinicalRe...kineticsandpharmacodynamicsofasingledoseofDRCystea...
(Date:11/23/2009)...ERYVILLE,Calif.,Nov.23/PRNewswire-FirstCall/--Neur...announcedtodaythatitsboardofdirectorshasdeclaredan...whichwillbepaidonDecember9,2009tostockholdersofrec...arydividendfollowsstockholderapprovalofthedissolut...solutionandanearlierextraordinarydividendof$0.75pe...
Breaking Medicine Technology:Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009 54518 1WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009 54518 2Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics Based Computer Modeling of Skin Biology 13562 1Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics Based Computer Modeling of Skin Biology 13562 2Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics Based Computer Modeling of Skin Biology 13562 3Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics Based Computer Modeling of Skin Biology 13562 4International Design Team Selected for Nigerian Hospital 54514 1International Design Team Selected for Nigerian Hospital 54514 2
...erging,as a breakthrough alternative to expensive ... an article published in the March issue of Journa...42-3), Ramakrishnan Lakshmy,PhD, explains that the...r,mass disease screening programs, especially in d... The article highlights a paper written by scienti...
...ace the,faulty CLN2 gene, which causes a neurodege...was able to slow significantly the rate of neurolo...per published online ahead of,print in the May 200...eer-reviewed journal published by Mary Ann Liebert...://www.liebertpub.com/hum , Late Infantile Neuron...
Other Medicine Technology:Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening 2Gene Therapy Slows Progression of Fatal Neurodegenerative Disease in Children 2
(Date:11/23/2009)...ov.23/PRNewswire/--VictoryPharma,Inc.("Victory")an...therextensionofVictory,sNAPRELANfranchise. ,, N...effrommildtomoderatepainandinflammationassociatedw...s.Itisalsodesignedforpatientssufferingfromrheumato...herapiesandneedadditionalanti-inflammatory/analges...
(Date:11/23/2009)...n changes offer clues to treatment advances, study...ws) -- The protein content of saliva changes as pe...s may help lead to a simple test to diagnose and t..., Human saliva contains numerous proteins that pl...r functions. Researchers are trying to find ways t...
(Date:11/23/2009)...fat on their waist in middle age are more than twi...er, reveals a new study from the Sahlgrenska Acade...cientific journal Neurology . , "Anyone carryin...k of dying prematurely due to a heart attack or st...the Sahlgrenska Academy. "If they nevertheless man...
(Date:11/23/2009)...he Medical College of Georgia is leading an initia...care of patients with sickle cell disease. , Mo...ty of Florida are partners in the initiative that ...a to serve as "medical homes" for patients, changi...ds them to the hospital and seeking better prevent...
(Date:11/23/2009)... Life-Science Focused Strategic Communicati... Communication Professionals , ...e Group, a life science-focused strategic communic...d the 2009 MarCom Gold Award in the design/website...Association of Marketing and Communication Profess...
Breaking Medicine News(10 mins):Health News:Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card 2Health News:Initiative could result in paradigm shift in the care of sickle cell patients 2Health News:Initiative could result in paradigm shift in the care of sickle cell patients 3Health News:Initiative could result in paradigm shift in the care of sickle cell patients 4Health News:Initiative could result in paradigm shift in the care of sickle cell patients 5Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 2Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 3
...can Heart Association (AHA) laid a new set of diet...which were offered by various organizations //such...e Pyramid and food recommendations from the Nation...by all are increased intake of fruit and vegetable...
...ya, a relatively rare form of mosquito-transmitted...adesh and hundreds are suffering from the disease,...s been reported in Madhya Pradesh for the first ti...e to the victim as a result of the arthritic sympt...
... symptom of Sj?gren’s (SHOW-grins) syndrome was fo... which lasts for long periods. Typical signs a...ntermittent blurry vision, a dry mouth that causes...ars. Other signs and symptoms may include dry skin...
...at is responsible for approving NHS treatments ha..., after it blocked the usage of an anti-cancer d...to asbestos will not be treated with the drug Alim...The group analyzed the cost effectiveness of the d...
...on is made easy but the new fat-busting laser trea...ritain and is claimed to be a quicker and less inv...lumps of fat in the thighs, bottom and in the doub...g Administration (FDA) has not approved to the pro...
... to a study by the investigators at John Hopkins C... improved by reporting as well as recording the me...kins researchers said ‘Human error rates are minim...ems are not new, but few studies have looked at th...
Other Medicine News:Health News:Voluntary Error-Reporting System Ensures Patient Safety 2Health News:Voluntary Error-Reporting System Ensures Patient Safety 3Health News:Voluntary Error-Reporting System Ensures Patient Safety 4
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: